Alamar Biosciences IPO: revenue, losses and offering terms from its S-1
Alamar Biosciences priced its IPO at $17 a share on 17 Apr 2026 and raised $191 million. Its shares trade on Nasdaq as ALMR. Revenue was $74.2 million in 2025, up 195% from 2024, with a net loss of $29.8 million.
Headlines
- Revenue, 2025
- $74M
- Up 195% on the year before
- Net loss, 2025
- $30M
- Revenue, First quarter of 2026
- $25M
- Up 92% on a year earlier
- IPO price
- $17
- $191M raised
Alamar Biosciences IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- ALMR
- IPO price
- $17
- Shares offered
- 11,250,000
- Raised
- $191M
- Registered
- $283M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners and Stifel
- First filed
- 27 Mar 2026
Alamar Biosciences revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $25M | - | -$47M |
| 2025 | $74M | -$31M | -$30M |
| First quarter of 2025 | $13M | - | - |
| First quarter of 2026 | $25M | -$13M | - |
Alamar Biosciences share structure and company facts
- Headquarters
- Fremont, California
Alamar Biosciences shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $17
- Priced 17 Apr 2026
- First close
- $22.00
- +29% on the IPO price
- Latest close
- $30.39
- +79% on the IPO price
Alamar Biosciences's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Alamar Biosciences's newest prospectus (424B4 filed 17 Apr 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.